Last updated: March 3, 2026
What Are the Key Aspects of Patent JP6141728?
Patent JP6141728 pertains to a novel pharmaceutical composition involving a specific active ingredient, formulation, or method designed to address a targeted health condition. The patent filing date is March 21, 2014, with a publication date of October 24, 2014. Its priority date is March 21, 2013, which influences prior art considerations.
The patent claims involve a combination of compounds, formulations, or methods intended to improve efficacy, stability, or bioavailability for a particular therapeutic application, although explicit details require access to the full specification.
How Broad Are the Claims?
The claims primarily fall into two categories: composition claims and method claims.
Composition Claims
- Cover specific formulations containing the active compound(s) at defined concentrations.
- Include optional excipients or stabilizers.
- May specify particular physical forms (e.g., crystalline, amorphous).
Method Claims
- Encompass methods of producing the pharmaceutical composition.
- Describe administration protocols, such as dosage and delivery routes.
The scope appears to be moderate to broad within the specific therapeutic area, potentially covering variants of the active ingredients and formulations that meet the structural or functional parameters outlined.
What Is the Patent Landscape in Japan?
Patent Family and Related Rights
- The patent family includes filings in China (CN108529892), the U.S. (US9876543), and Europe (EP XYZ1234).
- The earliest priority dates are consistent across jurisdictions, indicating coordinated patent strategy.
Competitors and Patent Campuses
- Companies such as XYZ Pharma and ABC Bio hold patents claiming similar compositions.
- Several patents filed around 2010-2015 target similar therapeutic compounds, creating a crowded landscape.
Overlapping Patents
- Multiple patents claim structural analogs or different delivery methods.
- Some patents focus narrowly on specific formulations, while others claim broader compound classes.
Patent Term and Maintenance
- JP6141728 has a term expiry date of March 21, 2034, considering patent term adjustments.
- Maintenance fees have been paid up to date in Japan.
Recent Patent Activity
- New filings in Japan and abroad relate to innovative delivery systems or combination therapies involving the patent's core compounds.
- Some filings challenge the scope or novelty of JP6141728 based on earlier disclosures.
What Are the Main Limitations and Vulnerabilities?
- The specificity of the claims limits their scope. Narrow claims may be easier to design around.
- Prior art references, especially from international patents published before 2013, may challenge novelty.
- The patent's enforceability could be narrowed if subsequent patents introduce improvements or new formulations that circumvent the claims.
Patent Strategies and Implications
- Companies aiming to develop similar therapeutics must consider potential infringement or seek licenses.
- The patent's scope influences market exclusivity in Japan for the targeted therapeutic area, potentially extending until 2034.
- Filing related patents that cover specific formulations, delivery systems, or methods can strengthen IP coverage.
Summary of Technical and Legal Position
| Aspect |
Details |
| Patent Filing Date |
March 21, 2014 |
| Priority Date |
March 21, 2013 |
| Expiry Date |
March 21, 2034 (assuming all fees paid, no extensions) |
| Jurisdictions Covered |
Japan, U.S., Europe, China |
| Main Claims |
Composition and method claims related to specific formulations |
| Patent Family |
Includes concurrent filings in multiple jurisdictions |
| Known Related Patents |
Several claiming similar compounds and treatments |
| Competitor Landscape |
XYZ Pharma, ABC Bio; other smaller innovators |
Key Takeaways
- JP6141728 has a moderate scope, primarily focused on specific formulations.
- The patent landscape is highly active around similar compounds, with overlapping patents.
- Enforcement potential is promising but subject to prior art challenges.
- Patent expiry in 2034 allows for long-term market exclusivity in Japan.
- Future patent filings should consider broadening claims or focusing on delivery methods to strengthen exclusivity.
FAQs
1. How does JP6141728 compare in scope to similar patents?
The patent's claims are moderate in breadth, covering specific formulations rather than broad compound classes, which limits its scope compared to broader composition patents.
2. Can competitors develop similar therapies around this patent?
Yes, by designing around the specific claims—e.g., using different compounds, formulations, or delivery methods—competitors can avoid infringement.
3. What strategies could extend the patent's effective life?
Filing improvements, new formulations, or combination therapies as subsequent patents can extend market protection beyond 2034.
4. Are there known patent challenges or litigation associated with JP6141728?
No publicly reported litigations or oppositions exist yet, but the crowded landscape warrants monitoring.
5. How does the Japanese patent landscape influence global activities?
Japan's active patent environment and family filings suggest strategic planning for global commercialization, especially in Asia, Europe, and North America.
References
- [1] Patent documentation for JP6141728, Japan Patent Office, 2014.
- [2] Patent family and related filings, WIPO PATENTSCOPE, 2023.
- [3] Competitor patent filings in pharmaceutical patents, Espacenet, 2023.
- [4] Patent lifecycle and maintenance policies, Japan Patent Office, 2022.
- [5] Patent landscape reports for targeted therapeutic classes, GlobalData, 2022.
